Dual SGLT1 and SGLT2 Inhibition: Sotagliflozin's Role in Contemporary Heart Failure Care

Course overview

Heart failure remains a leading cause of morbidity, mortality, and hospitalizations despite advances in guideline-directed therapy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed HF care, and sotagliflozin-the first dual SGLT2/SGLT1 inhibitor-adds a novel therapeutic dimension through combined renal, metabolic, and potential myocardial effects. Trials such as SOLOIST-WHF and SCORED show sotagliflozin reduces cardiovascular death, HF hospitalizations, and urgent visits while improving quality of life, with benefits across HF phenotypes and in high-risk patients with type 2 diabetes or chronic kidney disease. This course reviews HF pathophysiology, current standards of care, and the evidence supporting dual SGLT inhibition, emphasizing sotagliflozin's role, safety, and integration into modern management.